Crossflow Membrane Emulsification for Lipid Vesicle Size Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing lipid vesicles, such as liposomes and lipid nanoparticles, face challenges in scalability and reproducibility, particularly in achieving homogeneous distributions and controlled particle sizes for effective drug delivery, especially for nucleic acid-based therapeutics like mRNA vaccines.
Innovation Solution
A crossflow membrane emulsification apparatus using a tubular membrane with controlled flow directions and optional inserts is employed to disperse a lipid phase into an aqueous phase, allowing for the production of lipid vesicles with precise control over size and distribution, enabling scalable and reproducible manufacturing of liposomes or LNPs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods are used to produce lipid vesicles, then the process is simpler, but scalability and reproducibility are poor
Solution Approach 1:
The production process is segmented into distinct functional modules: a crossflow membrane emulsification apparatus for controlled vesicle formation, followed by separate purification and concentration steps. This modular segmentation enables each stage to be optimized independently, improving overall scalability and reproducibility while maintaining manageable process complexity
Solution Approach 2:
The patent employs precise control of physical-chemical parameters including flow rates, membrane pore sizes, lipid concentrations, and temperature conditions during vesicle formation. By systematically optimizing these parameters, the process achieves high reproducibility and scalability without requiring excessively complex equipment
2Manufacturing precision
If conventional production methods are used, then equipment is simpler, but particle size control and homogeneity are poor
Solution Approach 1:
The patent utilizes a crossflow membrane emulsification apparatus with controlled pore sizes to template lipid vesicle formation. The membrane pores act as physical templates that define vesicle size, enabling precise particle size control and narrow size distribution (low polydispersity) without requiring complex post-processing equipment
Solution Approach 2:
The crossflow membrane emulsification process incorporates feedback control through monitoring of flow rates, pressure differentials, and vesicle size distribution. This allows real-time adjustment of process parameters to maintain consistent particle size and homogeneity, improving manufacturing precision
3Quantity of substance
If encapsulation efficiency is increased, then more therapeutic agent is delivered, but production reproducibility decreases
Solution Approach 1:
The patent incorporates preliminary purification and concentration steps before final vesicle formulation. By pre-cleaning the lipid and therapeutic agent solutions and standardizing their concentrations, the process achieves both high encapsulation efficiency and reproducible production across batches
Solution Approach 2:
The patent employs composite lipid formulations containing multiple lipid types with complementary properties. This composite approach optimizes both encapsulation efficiency (through synergistic lipid interactions) and production reproducibility (through stable, well-defined material composition)
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves high reproducibility in encapsulation rates and particle size distribution, with polydispersity indices ≤0.3, facilitating the production of uniformly sized lipid vesicles suitable for drug and vaccine delivery, including mRNA-based vaccines, by controlling chemical and mechanical conditions during the formation process.
Implementation Method 1
A crossflow membrane emulsification apparatus using a tubular membrane with controlled flow directions and optional inserts is employed to disperse a lipid phase into an aqueous phase
Implementation Method 2
controlling provision of the first liquid phase in a first flow direction to a membrane, said membrane defining a plurality of pores; and controlling provision of the second liquid phase to the membrane in a crossflow to the first flow direction, via the plurality of pores
Data Source
AI summary
There is described a method of preparing lipid vesicles, said method comprising dispersing a first liquid phase in a second liquid phase; wherein said first liquid phase comprises a lipid phase and said second liquid phase comprises an aqueous phase; or said first liquid phase comprises an aqueous phase and said second liquid phase comprises a lipid phase; said method comprising controlling provision of the first liquid phase in a first flow direction to a membrane, said membrane defining a plurality of pores; and controlling provision of the second liquid phase to the membrane in a crossflow to the first flow direction, via the plurality of pores, to form a lipid vesicle suspension.